Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - INHIBITEX, INC. | exhibit1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): | December 13, 2010 |
Inhibitex, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
Delaware | 0-50772 | 742708737 |
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
of incorporation) | File Number) | Identification No.) |
9005 Westside Parkway, Alpharetta, Georgia | 30009 | |
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
Registrants telephone number, including area code: | 678-746-1100 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On December 13, 2010, Inhibitex, Inc. issued a press release announcing top-line results from the Phase III trial of FV-100 for the treatment of shingles. A copy of the press release is furnished as Exhibit 99.1 to this report.
Item 9.01 Financial Statements and Exhibits.
c) Exhibits
Exhibit No. Description of Exhibits
________________________________________
99.1 Press Release dated December 13, 2010.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Inhibitex, Inc. | ||||
December 13, 2010 | By: |
Russell H. Plumb
|
||
|
||||
Name: Russell H. Plumb | ||||
Title: Chief Executive Officer |
Exhibit Index
Exhibit No. | Description | |
|
|
|
99.1
|
Press Release dated December 13, 2010. |